KR960041173A - Irreversible HIV Protease Inhibitor with Anti-Aids (AIDS) Effect, Method of Preparation and Composition Comprising the Same - Google Patents

Irreversible HIV Protease Inhibitor with Anti-Aids (AIDS) Effect, Method of Preparation and Composition Comprising the Same Download PDF

Info

Publication number
KR960041173A
KR960041173A KR1019950013367A KR19950013367A KR960041173A KR 960041173 A KR960041173 A KR 960041173A KR 1019950013367 A KR1019950013367 A KR 1019950013367A KR 19950013367 A KR19950013367 A KR 19950013367A KR 960041173 A KR960041173 A KR 960041173A
Authority
KR
South Korea
Prior art keywords
compound
formula
phenyl
amino
valinyl
Prior art date
Application number
KR1019950013367A
Other languages
Korean (ko)
Other versions
KR0161140B1 (en
Inventor
윤흥식
최호일
정원희
손영찬
박지효
문광률
최낙현
김성천
김충렬
이태규
권영도
Original Assignee
성재갑
주식회사 Lg 화학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성재갑, 주식회사 Lg 화학 filed Critical 성재갑
Priority to KR1019950013367A priority Critical patent/KR0161140B1/en
Publication of KR960041173A publication Critical patent/KR960041173A/en
Application granted granted Critical
Publication of KR0161140B1 publication Critical patent/KR0161140B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/46—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids

Abstract

본 발명은 HIV 프로테아제의 억제제로서 유용한 신규 화합물 및 그의 제조방법 및 이를 포함하는 조성물에 관한 것으로서, 하기의 일반식(Ⅰ)의 시스-에폭사이드 구조를 갖는 화합물 및 그의 약학적으로 허용되는 염, 수화물 또는 용매화물은, HIV 프로테아제의 비가역적 억제제로서 억제 효과는 높은 반면 그 세포독성은 낮기 때문에, 에이즈 또는 HIV감염의 치료 또는 예방용 제제로서 유용하게 사용될 수 있다.The present invention relates to a novel compound useful as an inhibitor of HIV protease, a method for preparing the same, and a composition comprising the same, the compound having a cis-epoxide structure of the following general formula (I) and a pharmaceutically acceptable salt and hydrate thereof Alternatively, solvates can be usefully used as agents for the treatment or prevention of HIV or HIV infection because of their high inhibitory effect and low cytotoxicity as irreversible inhibitors of HIV proteases.

상기 식에서, R1, R2및 R3는 명세서중에서 정의한 바와 같다.In the above formula, R 1 , R 2 and R 3 are as defined in the specification.

Description

항 에이즈(AIDS)효과를 갖는 비가역적 HIV 프로테아제 억제제, 이의 제조방법 및 이를 포함하는 조성물Irreversible HIV Protease Inhibitor with Anti-Aids (AIDS) Effect, Method of Preparation and Composition Comprising the Same

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (6)

하기 일반식(Ⅰ)의 시스-에폭사이드 구조를 갖는 화합물 또는 그의 약제학적으로 허용되는 염, 수화물 또는 용매화물;A compound having a cis-epoxide structure of the general formula (I) or a pharmaceutically acceptable salt, hydrate or solvate thereof; 상기 식에서, R1은 탄소수 1 내지 8의 사이클릭 알킬 라디칼 또는 헤테로 사이클이고, R2및 R3는 서로 독립적으로 저급알킬, 방향족 라디칼로 치환된 저급 알킬, 탄소수 3 내지 8의 사이클릭 알킬, 사이클릭 알킬 라티칼로 치환된 저급 알킬 또는 방향족 라디칼이다.Wherein R 1 is a cyclic alkyl radical or heterocycle having 1 to 8 carbon atoms, and R 2 and R 3 are independently of each other lower alkyl, lower alkyl substituted with an aromatic radical, cyclic alkyl having 3 to 8 carbons, between Lower alkyl or aromatic radicals substituted with click alkyl radicals. 제1항에 있어서, R1이 2-티오펜, 2-푸라닐 또는 4-옥소-2,3-디하이드로-6,6-디페닐피란이고, R2가 이소프로필이며, R3가 벤질인 화합물.The compound of claim 1, wherein R 1 is 2-thiophene, 2-furanyl or 4-oxo-2,3-dihydro-6,6-diphenylpyran, R 2 is isopropyl, and R 3 is benzyl Phosphorus compounds. 제1항에 있어서, 〔(5S)-〔〔(N-2-티오펜카보닐)-β-메탄설포닐-L-발리닐〕아미노〕-(4R,3S)-에폭시-6-페닐-1-헥사노일〕-〔(2S)-〔1-페닐-3-메틸〕부틸〕아미드; 〔(5S)-〔〔(N-2-푸란카보닐)-β-메탄설포닐-L-발리닐〕아미노〕-(4R,3S)-에폭시-6-페닐-1-헥사노일〕-〔(2S)-〔1-페닐-3-메틸〕부틸〕아미드;〔(5S)-〔〔(N-피리딘카보닐)-β-메탄설포닐-L-발리닐〕아미노〕-(4R,3S)-에폭시-6-페닐-1-헥사노일〕-〔(2S)-〔1-페닐-3-메틸〕부틸〕아미드;〔(5S)-〔〔(N-3-피리딘카보닐)-β-메탄설포닐-L-발리닐〕아미노〕-(4R,3S)-에폭시-6-페닐-1-헥사노일〕-〔(2S)-〔1-페닐-3-메틸〕부틸〕아미드;〔(5S)-〔〔(N-2-(4-옥소-2,3-디하이드로-6,6-디메틸피란)카보닐 〕-β-메탄설포닐-L-발리닐〕아미노〕-(4R,3S)-에폭시-6-페닐-1-헥사노일〕-〔(2S)-〔1-페닐-3-메틸〕부틸〕아미드 및 이들의 약학적으로 허용되는 염, 수화물 및 용매화물 중에서 선택된 화합물.The compound according to claim 1, wherein ((5S)-[[(N-2-thiophencarbonyl) -β-methanesulfonyl-L-valinyl] amino]-(4R, 3S) -epoxy-6-phenyl- 1-hexanoyl]-[(2S)-[1-phenyl-3-methyl] butyl] amide; [(5S)-[[(N-2-furancarbonyl) -β-methanesulfonyl-L-valinyl] amino]-(4R, 3S) -epoxy-6-phenyl-1-hexanoyl]-[ (2S)-[1-phenyl-3-methyl] butyl] amide; [(5S)-[[(N-pyridinecarbonyl) -β-methanesulfonyl-L-valinyl] amino]-(4R, 3S ) -Epoxy-6-phenyl-1-hexanoyl]-[(2S)-[1-phenyl-3-methyl] butyl] amide; [(5S)-[[(N-3-pyridinecarbonyl) -β -Methanesulfonyl-L-valinyl] amino]-(4R, 3S) -epoxy-6-phenyl-1-hexanoyl]-[(2S)-[1-phenyl-3-methyl] butyl] amide; [ (5S)-[[(N-2- (4-oxo-2,3-dihydro-6,6-dimethylpyran) carbonyl] -β-methanesulfonyl-L-valinyl] amino]-(4R , 3S) -epoxy-6-phenyl-1-hexanoyl]-[(2S)-[1-phenyl-3-methyl] butyl] amide and pharmaceutically acceptable salts, hydrates and solvates thereof . 일반식(Ⅱ)의 화합물을 일반식(Ⅲ)의 화합물과 커플링 반응시킨 후 산화시켜 일반식(Ⅳ)의 화합물을 얻고; 일반식(Ⅳ)의 화합물을 탈보호시킨 후 일반식(Ⅴ)의 화합물을 커플링시켜 일반식(Ⅵ)의 화합물을 얻고; 일반식(Ⅴ)의 화합물을 탈보호시킨 후 R1-COOH를 커플링시키는 것을 특징으로 하는 일반식(Ⅰ)의 화합물의 제조방법.Coupling the compound of formula (II) with the compound of formula (III) and then oxidizing to obtain a compound of formula (IV); Deprotecting the compound of formula (IV) followed by coupling the compound of formula (V) to obtain a compound of formula (VI); A method for preparing a compound of formula (I), characterized by coupling R 1 -COOH after deprotecting the compound of formula (V). 상기에서, R1, R2및 R3는 제1항에서 정의한 바와 같고, ⓟ는 아미노기 보호그룹이다.In the above, R 1 , R 2 and R 3 are as defined in claim 1, ⓟ is an amino group protecting group. 제4항에 있어서, 일반식(Ⅶ)의 화합물을 비티그 반응시켜 일반식(Ⅷ)의 화합물을 수득한 다음, 이를 산촉매 존재하에 t-부탄올중에서 용매의 환류온도로 가열하는 것에 의해 상기 일반식(Ⅱ)의 화합물을 제조하는 단계를 더욱 포함하는 것을 특징으로 하는 방법.The compound of formula (IV) according to claim 4, wherein the compound of formula (IV) is subjected to a BIG reaction to obtain a compound of formula (IV), which is then heated to the reflux temperature of the solvent in t-butanol in the presence of an acid catalyst. Further comprising preparing the compound of (II). 상기에서, X는 할로겐 원자이고, ⓟ는 아미노기 보호그룹이다.In the above, X is a halogen atom, ⓟ is an amino group protecting group. 제1항 내지 제3항 중 어느 한 항의 화합물 또는 그의 약학적으로 허용되는 염, 수화물 또는 용매화합물 유효성분으로 포함하는, 후천성 면역결핍증 또는 인간 면역결핍 바이러스(HIV)감염의 예방 또는 치료에 유용한 조성물.A composition useful for the prevention or treatment of acquired immunodeficiency or human immunodeficiency virus (HIV) infection, comprising as an active ingredient the compound of any one of claims 1 to 3 or a pharmaceutically acceptable salt, hydrate or solvate thereof. . ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950013367A 1995-05-26 1995-05-26 Irrevesible hiv protease inhibitors with anti-aids effect, process for the preparation thereof and compositions containing the same KR0161140B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019950013367A KR0161140B1 (en) 1995-05-26 1995-05-26 Irrevesible hiv protease inhibitors with anti-aids effect, process for the preparation thereof and compositions containing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019950013367A KR0161140B1 (en) 1995-05-26 1995-05-26 Irrevesible hiv protease inhibitors with anti-aids effect, process for the preparation thereof and compositions containing the same

Publications (2)

Publication Number Publication Date
KR960041173A true KR960041173A (en) 1996-12-19
KR0161140B1 KR0161140B1 (en) 1998-12-01

Family

ID=19415504

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950013367A KR0161140B1 (en) 1995-05-26 1995-05-26 Irrevesible hiv protease inhibitors with anti-aids effect, process for the preparation thereof and compositions containing the same

Country Status (1)

Country Link
KR (1) KR0161140B1 (en)

Also Published As

Publication number Publication date
KR0161140B1 (en) 1998-12-01

Similar Documents

Publication Publication Date Title
AU551239B2 (en) Substituted acyl derivatives of 1,2,3,4-tetrahydro isoquinoline-3-carboxylic acids
IL144826A0 (en) Amide compounds and pharmaceutical compositions containing the same
NO913750L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE HETEROCYCLIC DERIVATIVES.
NO179638C (en) Analogous process for the preparation of thiazole derivatives
NO862208D0 (en) PROCEDURE FPR PREPARATION OF HETEROCYCLIC COMPOUNDS.
TW369535B (en) A pyrazolopyridine compound and the process for preparing thereof
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
KR930004296A (en) New (2-alkyl-3-pyridyl) methylpiperazine Derivatives
DK96786A (en) AMINO ACID DERIVATIVES
NO172893C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF NEW THERAPEUTICALLY ACTIVE CEFEM RELATIONS
AU2003238697A1 (en) Par-2-activating peptide derivative and pharmaceutical composition using the same
KR960041173A (en) Irreversible HIV Protease Inhibitor with Anti-Aids (AIDS) Effect, Method of Preparation and Composition Comprising the Same
KR960041171A (en) Irreversible HIV Protease Inhibitor with Anti-Aids (AIDS) Effect, Preparation Method thereof, and Composition Comprising the Same
KR960000878A (en) Novel Human Immunodeficiency Virus (HIV) Protease Inhibiting Compounds and Methods for Making the Same
KR960041174A (en) Irreversible HIV Protease Inhibitor with Anti-Aids (AIDS) Effect, Method of Preparation and Composition Comprising the Same
KR940021515A (en) 2,4-diamino-3-hydroxycarboxylic acid derivative
KR960041172A (en) Irreversible HIV Protease Inhibitor with Anti-Aids (AIDS) Effect, Method of Preparation and Composition Comprising the Same
PT89492A (en) PREPARATION PROCESS OF NEW THERAPEUTICALLY ACTIVE THIOFORMAMIDE DERIVATIVES
WO1993004059A1 (en) 4-acylaminoimidazole derivative
EP0222371A3 (en) Thiazolidine derivatives, process for their preparation and pharmaceutical compositions
EA199900460A1 (en) DERIVATIVES OF BENZULSULPHONE AMID AND MEDICINES CONTAINING MENTIFIED DERIVATIVES
CA2368650A1 (en) Viral treatment
FI89594C (en) PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICAL PROPERTIES OF PYRROLIDINE INFOERING
KR970020097A (en) Irreversible Human Immunodeficiency Virus (HIV) Protease Inhibitors with Anti-AIDS (AIDS) Effects and Methods of Making the Same
KR950011430A (en) Novel Human Immunodeficiency Virus (HIV) Protease Inhibitory Compounds Having Anti-AIDS Effects and Methods for Preparing the Same

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020729

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee